Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aventis/Regeneron VEGF Colorectal Cancer Indication Part Of $500 Mil. Deal

Executive Summary

Aventis and Regeneron are pursuing a colorectal indication for Regeneron's vascular endothelial growth factor trap after seeing positive results from Genentech's Phase III VEGF inhibitor Avastin

You may also be interested in...

Aventis Plans To Launch Genasense, Ketek and Apidra In 2004

The launch of Genasense will be a key step in Aventis' plans to build its oncology franchise, Chief Operating Officer Richard Markham said Jan. 13 during the J.P. Morgan health care conference in San Francisco

Avastin To Be Standard Add-On Agent In Colorectal Cancer, Genentech Says

Genentech believes that its investigational agent Avastin will become standard add-on therapy to chemotherapy in the treatment of colorectal cancer after unveiling data demonstrating that the VEGF inhibitor "markedly" improves survival in first-line metastatic disease

Axokine Obesity Trial Setback Weighs Down Regeneron On Wall Street

Regeneron will explore ways to fine-tune its investigational obesity agent Axokine to increase the percentage of patients that do not develop antibodies to the protein, CEO Leonard Schleifer, MD/PhD, said

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts